Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ebola*:

A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay. Singh K et al. J Immunol Methods. (2018)

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. Cui Q et al. Viruses. (2018)

Ebola Taught Value of Preparation, Vigilance. Morrissey J et al. Health Prog. (2017)

Search results

Items: 1 to 20 of 7892

1.

Ebola detectives race to identify hidden sources of infection as outbreak spreads.

Maxmen A.

Nature. 2018 Dec;564(7735):174-175. doi: 10.1038/d41586-018-07618-0. No abstract available.

PMID:
30531881
2.

Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.

Cattapan A, Browne K, Halperin DM, Di Castri A, Fullsack P, Graham J, Langley JM, Taylor BA, McNeil SA, Halperin SA.

Vaccine. 2018 Dec 6. pii: S0264-410X(18)31527-5. doi: 10.1016/j.vaccine.2018.11.014. [Epub ahead of print]

PMID:
30528592
3.

Randomised controlled trial begins for Ebola therapeutics.

Nakkazi E.

Lancet. 2018 Dec 1;392(10162):2338. doi: 10.1016/S0140-6736(18)33011-3. No abstract available.

PMID:
30527603
4.

FRONTLINE: a new treatment facility for Ebola virus disease.

Devi S.

Lancet. 2018 Dec 8;392(10163):2428. doi: 10.1016/S0140-6736(18)33118-0. No abstract available.

PMID:
30527407
5.

[Ebola virus L protein harbors a new enzymatic activity involved in the internal methylation of RNAs].

Martin B, Valle C, Coutard B, Canard B, Debart F, Decroly É.

Med Sci (Paris). 2018 Nov;34(11):919-921. doi: 10.1051/medsci/2018230. Epub 2018 Dec 10. French. No abstract available.

PMID:
30526829
6.

A smartphone-based rapid telemonitoring system for Ebola and Marburg disease surveillance.

Natesan M, Wu SW, Chen CI, Jensen SM, Karlovac N, Dyas BK, Mudanyali O, Ulrich RG.

ACS Sens. 2018 Dec 7. doi: 10.1021/acssensors.8b00842. [Epub ahead of print]

PMID:
30525467
7.

Black-hole bounty, Ebola emergency and UK science minister resigns.

[No authors listed]

Nature. 2018 Dec;564(7734):10-11. doi: 10.1038/d41586-018-07590-9. No abstract available.

PMID:
30518906
8.

ANTIBODY-MEDIATED PROTECTIVE MECHANISMS INDUCED BY A TRIVALENT PARAINFLUENZA-VECTORED EBOLAVIRUS VACCINE.

Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE Jr, Alter G, Bukreyev A.

J Virol. 2018 Dec 5. pii: JVI.01845-18. doi: 10.1128/JVI.01845-18. [Epub ahead of print]

PMID:
30518655
10.

Jean-Jacques Muyembe Tamfum: a life's work on Ebola.

[No authors listed]

Bull World Health Organ. 2018 Dec 1;96(12):804-805. doi: 10.2471/BLT.18.031218.

11.

Sequencing in the time of Ebola.

Van Puyvelde S, Argimon S.

Nat Rev Microbiol. 2019 Jan;17(1):5. doi: 10.1038/s41579-018-0130-0. No abstract available.

PMID:
30504802
12.

Contemporary anti-Ebola drug discovery approaches and platforms.

Schneider-Futschik EK, Hoyer D, Khromykh A, Baell JB, Marsh G, Baker MA, Li J, Velkov T.

ACS Infect Dis. 2018 Dec 5. doi: 10.1021/acsinfecdis.8b00285. [Epub ahead of print]

PMID:
30516045
13.

Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77.

Cao P, Bai H, Wang X, Che J.

Sci Rep. 2018 Dec 4;8(1):17628. doi: 10.1038/s41598-018-35964-6.

14.

Persistence and Sexual Transmission of Filoviruses.

Schindell BG, Webb AL, Kindrachuk J.

Viruses. 2018 Dec 2;10(12). pii: E683. doi: 10.3390/v10120683. Review.

15.

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus.

Cui Q, Cheng H, Xiong R, Zhang G, Du R, Anantpadma M, Davey RA, Rong L.

Viruses. 2018 Nov 30;10(12). pii: E678. doi: 10.3390/v10120678.

16.

Standardized focus assay protocol for biosafety level four viruses.

Ackermann-Gäumann R, Siegrist D, Züst R, Signer J, Lenz N, Engler O.

J Virol Methods. 2018 Dec 1;264:51-54. doi: 10.1016/j.jviromet.2018.12.002. [Epub ahead of print]

PMID:
30513365
17.

Ebola Virus Infection Associated with Transmission from Survivors.

Den Boon S, Marston BJ, Nyenswah TG, Jambai A, Barry M, Keita S, Durski K, Senesie SS, Perkins D, Shah A, Green HH, Hamblion EL, Lamunu M, Gasasira A, Mahmoud NO, Djingarey MH, Morgan O, Crozier I, Dye C.

Emerg Infect Dis. 2019 Feb 17;25(2). doi: 10.3201/eid2502.181011. [Epub ahead of print]

18.

Returning our Ebola medals: our opposition to the hostile environment within the NHS.

Burn H.

Br J Gen Pract. 2018 Dec;68(677):580. doi: 10.3399/bjgp18X700013. No abstract available.

PMID:
30498149
19.

Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.

Kochhar S, Excler JL, Bok K, Gurwith M, McNeil MM, Seligman SJ, Khuri-Bulos N, Klug B, Laderoute M, Robertson JS, Singh V, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2018 Nov 26. pii: S0264-410X(18)31235-0. doi: 10.1016/j.vaccine.2018.08.085. [Epub ahead of print]

20.

Integrated Disease Surveillance and Response (IDSR) in Malawi: Implementation gaps and challenges for timely alert.

Joseph Wu TS, Kagoli M, Kaasbøll JJ, Bjune GA.

PLoS One. 2018 Nov 29;13(11):e0200858. doi: 10.1371/journal.pone.0200858. eCollection 2018.

Supplemental Content

Loading ...
Support Center